Tyme Technologies (TYME) sent out a press release Friday trumpeting that its cancer drug, SM-88, “improves survival” in a Phase 2 study of patients with advanced pancreatic cancer. However, the study raises two big red flags.
First, it is impossible to conclude that based on the study in question. Second, the results were less impressive on the main efficacy goal of the study.
The new data fall below the expectations of investors, but the company says it believes the drug is providing a big survival benefit for metastatic pancreatic cancer patients who have failed two other drug regimens, and it plans to discuss plans for approval with the Food and Drug Administration.
About the Author Reprints
